Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells.
about
Recent Advances in Lentiviral Vaccines for HIV-1 InfectionPros and Cons of Antigen-Presenting Cell Targeted Tumor VaccinesSignal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapyImmunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivoDendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in micePreferential lentiviral targeting of astrocytes in the central nervous system.Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model.Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancerA TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responsesExpression of a biotin acceptor peptide-containing protein with potential incorporation on the lentiviral envelope as a viral surface engineering platformParticle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I InterferonSpecific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13.Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs.Immunogenicity of targeted lentivectors.Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery.The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome.Targeting of human antigen-presenting cell subsets.Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.Development of an adenovirus vector vaccine platform for targeting dendritic cells.Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of LymphocytesThe Journey of Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
P2860
Q26742169-7E468388-D134-4BB2-AE2C-D4A99261D3B4Q27013679-24EA1AE5-20EE-4CFC-8CD9-F62596BA43A4Q28080262-630599C7-D271-4E18-8877-EFAC7671006CQ33945680-0AD0E6BA-CB00-4216-87C4-E81A479E1CD2Q34472125-CDFDAD0E-6FE2-4CE9-821C-908C5754AF03Q35009241-A0740B05-8281-4042-8F69-35C63696CA21Q35798966-10B4628F-05CD-4008-8D36-C7C5D76A7980Q35828574-3FB028B5-3349-495B-8128-1D0C04C48096Q35990046-591A65B9-3B5A-431F-A562-285CC4C13CBDQ36216709-4837E8EF-6C1E-4104-AE30-13BECEFE2F73Q37254639-E2566509-8108-479D-9722-2E13F09AE76CQ37358531-D27F670F-D792-483C-83D3-B2A1C13A09FAQ37447879-AF4ADB30-78E1-472D-9540-52F41FFC2601Q37718447-6075D966-095A-4907-880D-5C45CB67555EQ38554795-5BF675DF-121D-43AE-9095-3C3B3553DA3DQ40187007-33E625BF-92EC-4EE8-B3F4-7791AA2EDA03Q41351026-83F7F517-35CB-4092-80DA-83666EA27C72Q42283131-AD261B82-3782-4E3B-A21D-D78C5DF75A07Q47121798-73D909D7-01E0-44DE-998C-3DADD87ADAD4Q47248134-754143CB-CD42-4EB4-8B5C-2E1A9078A476Q58726929-1FDEE6D3-0172-488E-B9FA-7C75F4A5F605Q58750585-628FBB87-1289-4F37-A6C5-D5A14B7EA07F
P2860
Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Development of the Nanobody di ...... s to antigen-presenting cells.
@ast
Development of the Nanobody di ...... s to antigen-presenting cells.
@en
type
label
Development of the Nanobody di ...... s to antigen-presenting cells.
@ast
Development of the Nanobody di ...... s to antigen-presenting cells.
@en
prefLabel
Development of the Nanobody di ...... s to antigen-presenting cells.
@ast
Development of the Nanobody di ...... s to antigen-presenting cells.
@en
P2093
P2860
P356
P1433
P1476
Development of the Nanobody di ...... s to antigen-presenting cells.
@en
P2093
C Goyvaerts
J Dingemans
K De Groeve
K Thielemans
P De Baetselier
S Van Lint
P2860
P2888
P304
P356
10.1038/GT.2011.206
P577
2012-01-12T00:00:00Z